"Our goal is to help companies accelerate the research and development of next-generation cancer immunotherapies, so clinicians can treat cancer patients more effectively," said
Financial terms of the agreement were not disclosed.
"Novel PET biomarkers are essential to better understand and rationally develop next-generation immunotherapies, and ImaginAb's CD8 ImmunoPET technology is designed to give us a non-invasive whole-body view of immune system activity," said
For more information please see www.imaginab.com.
About Nektar Therapeutics
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Media Contact for ImaginAb:
View original content to download multimedia:http://www.prnewswire.com/news-releases/imaginab-announces-immuno-oncology-license-and-clinical-trial-collaboration-with-nektar-therapeutics-300770672.html